Comparison

Lixisenatide vs. Tirzepatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Tirzepatide

Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Lixisenatide	Tirzepatide
Switzerland	—	Prescription
Germany	Prescription	Prescription
JP	Prescription	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Lixisenatide and Tirzepatide?: Lixisenatide is classified as "Metabolic", while Tirzepatide is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lixisenatide or Tirzepatide?: The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lixisenatide and Tirzepatide in Germany and the United States?: Germany: Lixisenatide — Prescription, Tirzepatide — Prescription. United States: Lixisenatide — Unapproved, Tirzepatide — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Lixisenatide

Tirzepatide

Switzerland

—

Prescription

Germany

Prescription

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Lixisenatide and Tirzepatide?

Lixisenatide is classified as "Metabolic", while Tirzepatide is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lixisenatide or Tirzepatide?

The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lixisenatide and Tirzepatide in Germany and the United States?

Germany: Lixisenatide — Prescription, Tirzepatide — Prescription. United States: Lixisenatide — Unapproved, Tirzepatide — Prescription. These are factual summaries with source and review date on the individual pages.